Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Serina Therapeutics Inc (Serina Therapeutics) is a company that develops proprietary drugs to treat neurological diseases. The company's pipeline products include SER-252 (POZ-apomorphine) which treats advanced Parkinson’s; SER-270 for Tardive Dyskinesia, POZ-RNA which targets RNA therapeutics; POZ-ADCs for oncology. It advances novel RNA medicines in vaccine immunology, cancer immunoRX, and gene therapy. The company leverages its proprietary POZ platform technology, which is designed for programmable, targeted delivery of small molecules. It collaborates with pharmaceutical and biotechnology companies to develop novel therapeutics using its POZ platform. Therapeutics is headquartered in Huntsville, Alabama, the US.
Headquarters
United States of America
Address
Suite 2001, 601 Genome Way, Huntsville, Alabama, 35806
Website
serinatherapeutics.com
Telephone
1 256 3270548
No of Employees
13
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SER (AFM)
Revenue (2024)
$130,000
132.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-72.2%
(2024 vs 2023)
Market Cap*
$35.2M
Net Profit Margin (2024)
XYZ
25.8%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | POZ |
| SER-252 - Advanced Parkinson's | |
| SER-270 - Tardive Dyskinesia | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Serina Therapeutics Inc | Ascendis Pharma AS | Cerecin Pte Ltd | Curemark LLC |
|---|---|---|---|---|
| Headquarters | United States of America | Denmark | Singapore | United States of America |
| City | Huntsville | Hellerup | Singapore City | Rye BrooK |
| State/Province | Alabama | - | - | New York |
| No. of Employees | 13 | 1,189 | - | - |
| Entity Type | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Simba Gill, PhD | Chairman | Executive Board | 2024 | 61 |
| Steve Ledger | Chief Executive Officer; Director | Executive Board | 2024 | 65 |
| Greg Bailey | Co-Chairman | Executive Board | 2026 | - |
| Gregory S. Curhan | Chief Financial Officer | Senior Management | 2024 | - |
| Greg Curhan | Chief Financial Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer